Dr. Galvez is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1801 W Taylor St 1e
Chicago, IL 60612Phone+1 312-355-1625Fax+1 312-355-1625
Summary
- Dr. Carlos Galvez practices in the Division of Hematology & Oncology at UI Health. Dr. Galvez is a malignant hematologist who specializes in the treatment of blood cancers, with a focus on lymphoma, cellular therapy, including CAR T-cell therapy, and clinical trials. He continuously keeps up with the latest cancer literature and serves as an advocate for patients to ensure they can receive the most up-to-date medical care. During clinic visits, all potential management options are carefully and thoroughly discussed with each patient and all questions are answered. Dr. Galvez firmly believes that high-level medical care is a fundamental human right, and he enjoys working with patients from all nationalities and socioeconomic backgrounds. It is his true privilege to be able to establish long-term relationships with patients and work together with the shared goal of improving both their health and quality of life.
Education & Training
- McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 2016 - 2019
- University of Illinois College of MedicineClass of 2016
Certifications & Licensure
- IL State Medical License 2016 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy Start of enrollment: 2023 Mar 31
Roles: Contact
Publications & Presentations
PubMed
- 35 citationsCancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patientsYoung Kwang Chae, Carlos Galvez, Jonathan F. Anker, Wade T. Iams, Manali Bhave
Cancer Treatment Reviews. 2018-02-01 - 22 citationsPeri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL.Joanna Zurko, Imran Nizamuddin, Narendranath Epperla, Kevin David, Jonathon B Cohen
Blood Advances. 2023-06-27 - 17 citationsThrombocytosis and Thrombosis: Is There Really a Correlation?Carlos Galvez, Brady L. Stein
Current Hematologic Malignancy Reports. 2020-05-12
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: